(Q39325984)

11 September 2017

Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

11 September 2017

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Antonio García-Ruiz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

G Izquierdo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Granell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Brosa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

23 October 2013

1 reference

11 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

210-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

10.1016/J.NRL.2013.04.003

3 June 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24161412%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference